These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6349865)

  • 1. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study.
    Braun JJ; Birkenhäger-Frenkel DH; Rietveld AH; Juttmann JR; Visser TJ; Birkenhäger JC
    Clin Endocrinol (Oxf); 1983 Aug; 19(2):265-73. PubMed ID: 6349865
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
    Geusens P; Dequeker J
    Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium. Evaluation of bone histomorphometry in osteoporotics and age matched controls.
    Lindholm TS; Nilsson OS; Widhe T; Elmsted E; Eriksson S
    Acta Vitaminol Enzymol; 1982; 4(1-2):179-84. PubMed ID: 7124565
    [No Abstract]   [Full Text] [Related]  

  • 4. Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Eriksson S; Lindholm TC
    Ital J Orthop Traumatol; 1984 Jun; 10(2):187-201. PubMed ID: 6432736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Eriksson S
    Scand J Rheumatol; 1982; 11(1):55-7. PubMed ID: 7063813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study.
    Shikari M; Kushida K; Yamazaki K; Nagai T; Inoue T; Orimo H
    Endocr J; 1996 Apr; 43(2):211-20. PubMed ID: 9026268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1 alpha-hydroxyvitamin D3 in intestinal calcium malabsorption. A pilot study.
    Hylander E; Jarnum S
    Scand J Gastroenterol; 1980; 15(4):443-8. PubMed ID: 7433906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of osteoporosis with 1-alpha-hydroxycholecalciferol and calcium.
    Hoikka V; Alhava EM; Aro A; Karjalainen P; Rehnberg V
    Acta Med Scand; 1980; 207(3):221-4. PubMed ID: 6989171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE; Melsen F; Christensen MS; Hansen HE; Rodbro P; Johannsen A
    Clin Nephrol; 1977 Oct; 8(4):429-34. PubMed ID: 923161
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
    Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
    Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calcifediol on calcified tissue in uremia.
    Kleinman LM; Letteri JM; Asad SN; Ellis KJ; Cohn SH
    Arch Intern Med; 1978 May; 138 Spec No():864-5. PubMed ID: 646575
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Nilsson OS; Elmstedt E; Eriksson SA; Lindholm TC; Kyhle BR
    Acta Vitaminol Enzymol; 1981; 3(3):170-6. PubMed ID: 7347489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
    Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
    Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of 1-alpha oxyvitamin D3 on bone tissue in systemic osteoporosis].
    Rodionova SS; Zatsepin ST; Shvets VN
    Ortop Travmatol Protez; 1989 Feb; (2):37-40. PubMed ID: 2726218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
    Weber K; Goldberg M; Stangassinger M; Erben RG
    J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral content in chronic renal failure during long-term treatment with 1alpha-hydroxycholecalciferol.
    Madsen S; Olgaard K; Ladefoged J
    Acta Med Scand; 1978; 203(5):385-9. PubMed ID: 665304
    [No Abstract]   [Full Text] [Related]  

  • 20. [The efficacy of combined use of 1 alpha-hydroxyvitamin D3 with calcium supplements in the treatment of osteoporosis].
    Yoshikawa S; Ohno A; Moro K; Matsumoto M; Nemoto H; Seki H; Kaneko N; Hosokawa O; Ishijima H
    Nihon Seikeigeka Gakkai Zasshi; 1988 Aug; 62(8):723-32. PubMed ID: 3235892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.